BEDFORD -
Presentations at Eyecelerator (associated @ ASCRS 2024)
Session Title: 'Presenting Company Showcases' Session Date/Time:
Presentations at ASCRS at the
Title: Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: Results from a Phase 2 Clinical Trial
Session Title: Glaucoma (Procedures and Medications)
Session Date/Time:
Location: Meeting Level 2, Room 257B
Presenter:
Title: Incidence of Safety Events Following Cataract Surgery with Intracanalicular Dexamethasone: A Study of 50,000 Eyes Using the IRIS Registry
Session Title: Medications (Preoperative, Postoperative, Intraoperative)
Session Date/Time:
Location: Meeting Level 2, Room 257A
Presenter:
Title: Characteristics of Cataract Surgery Patients Receiving Intracanalicular Dexamethasone Insert: An IRIS Registry Analysis of 50,000 Eyes
Session Title: Medications (Preoperative, Postoperative, Intraoperative)
Session Date/Time:
Location: Meeting Level 2, Room 257A
Presenter:
About
Ocular's expertise in the formulation, development and commercialization of innovative therapies and the ELUTYX platform supported the development and launch of its first commercial drug product, DEXTENZA, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. ELUTYX is also the foundation for two other clinical-stage assets, OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease, as well as several preclinical programs.
About DEXTENZA
DEXTENZA is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the inner portion of the lower eyelid, and into the canaliculus, and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives. DEXTENZA resorbs and exits the nasolacrimal system without the need for removal.
Contact:
Email: dnotman@ocutx.com
Email: jallaire@lifesciadvisors.com
(C) 2024 Electronic News Publishing, source